ATE501121T1 - 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen - Google Patents
4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungenInfo
- Publication number
- ATE501121T1 ATE501121T1 AT07728049T AT07728049T ATE501121T1 AT E501121 T1 ATE501121 T1 AT E501121T1 AT 07728049 T AT07728049 T AT 07728049T AT 07728049 T AT07728049 T AT 07728049T AT E501121 T1 ATE501121 T1 AT E501121T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- phenylmethylüpiperidine
- methanesulfoate
- fluorphenoxy
- synthetic methods
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 3- FLUORPHENOXY Chemical class 0.000 title 1
- 238000010189 synthetic method Methods 0.000 title 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- ZEFXAHXKTLEBQA-UHFFFAOYSA-N 4-[(3-fluorophenoxy)-phenylmethyl]piperidine;methanesulfonic acid Chemical compound CS(O)(=O)=O.FC1=CC=CC(OC(C2CCNCC2)C=2C=CC=CC=2)=C1 ZEFXAHXKTLEBQA-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06380112A EP1854785A1 (de) | 2006-05-12 | 2006-05-12 | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulponat: Anwendungen, Verfahren zur Synthese und pharmazeutische Zusammensetzungen |
| US11/486,350 US20070265306A1 (en) | 2006-05-12 | 2006-07-13 | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| PCT/EP2007/053582 WO2007131846A1 (en) | 2006-05-12 | 2007-04-12 | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE501121T1 true ATE501121T1 (de) | 2011-03-15 |
Family
ID=37061190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07728049T ATE501121T1 (de) | 2006-05-12 | 2007-04-12 | 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20070265306A1 (de) |
| EP (2) | EP1854785A1 (de) |
| JP (1) | JP2009536962A (de) |
| KR (1) | KR20090009971A (de) |
| CN (1) | CN101443312B (de) |
| AT (1) | ATE501121T1 (de) |
| AU (1) | AU2007251663B2 (de) |
| BR (1) | BRPI0710856A2 (de) |
| CA (1) | CA2651933A1 (de) |
| CY (1) | CY1111460T1 (de) |
| DE (1) | DE602007013040D1 (de) |
| DK (1) | DK2032534T3 (de) |
| ES (1) | ES2362683T3 (de) |
| HR (1) | HRP20110333T1 (de) |
| MX (1) | MX2008014439A (de) |
| MY (1) | MY148406A (de) |
| NO (1) | NO20085052L (de) |
| NZ (1) | NZ572714A (de) |
| PL (1) | PL2032534T3 (de) |
| RS (1) | RS51858B (de) |
| RU (1) | RU2412169C2 (de) |
| SI (1) | SI2032534T1 (de) |
| WO (1) | WO2007131846A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1854785A1 (de) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulponat: Anwendungen, Verfahren zur Synthese und pharmazeutische Zusammensetzungen |
| JP5405571B2 (ja) * | 2008-07-24 | 2014-02-05 | セラヴァンス， インコーポレーテッド | ３−（フェノキシフェニルメチル）ピロリジン化合物 |
| US20100267743A1 (en) * | 2009-04-15 | 2010-10-21 | Stangeland Eric L | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| CN102471258A (zh) * | 2009-07-13 | 2012-05-23 | 施万制药 | 3-苯氧基甲基吡咯烷化合物 |
| JP5714580B2 (ja) | 2009-07-21 | 2015-05-07 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ３−フェノキシメチルピロリジン化合物 |
| WO2012051103A1 (en) | 2010-10-11 | 2012-04-19 | Theravance, Inc. | Serotonin reuptake inhibitors |
| WO2012075239A1 (en) | 2010-12-03 | 2012-06-07 | Theravance, Inc. | Serotonin reuptake inhibitors |
| US9002322B2 (en) * | 2011-09-29 | 2015-04-07 | Apple Inc. | Authentication with secondary approver |
| CN104887675B (zh) * | 2014-03-05 | 2018-08-07 | 江苏恩华药业股份有限公司 | [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1203149A (en) * | 1968-06-10 | 1970-08-26 | Ici Ltd | Piperidine derivatives |
| ES2157148B1 (es) * | 1998-11-18 | 2002-03-01 | Faes Fabrica Espanola De Produ | Nuevas piperidinas 4-sustituidas. |
| US6518284B2 (en) * | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
| AU2005238296A1 (en) * | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
| EP1854785A1 (de) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulponat: Anwendungen, Verfahren zur Synthese und pharmazeutische Zusammensetzungen |
-
2006
- 2006-05-12 EP EP06380112A patent/EP1854785A1/de not_active Withdrawn
- 2006-07-13 US US11/486,350 patent/US20070265306A1/en not_active Abandoned
-
2007
- 2007-04-12 WO PCT/EP2007/053582 patent/WO2007131846A1/en not_active Ceased
- 2007-04-12 US US12/299,907 patent/US20100004283A1/en not_active Abandoned
- 2007-04-12 PL PL07728049T patent/PL2032534T3/pl unknown
- 2007-04-12 MY MYPI20084507A patent/MY148406A/en unknown
- 2007-04-12 HR HR20110333T patent/HRP20110333T1/hr unknown
- 2007-04-12 NZ NZ572714A patent/NZ572714A/en not_active IP Right Cessation
- 2007-04-12 MX MX2008014439A patent/MX2008014439A/es active IP Right Grant
- 2007-04-12 KR KR1020087030170A patent/KR20090009971A/ko not_active Ceased
- 2007-04-12 BR BRPI0710856-7A patent/BRPI0710856A2/pt not_active IP Right Cessation
- 2007-04-12 AU AU2007251663A patent/AU2007251663B2/en not_active Ceased
- 2007-04-12 RU RU2008148941/04A patent/RU2412169C2/ru not_active IP Right Cessation
- 2007-04-12 EP EP07728049A patent/EP2032534B1/de active Active
- 2007-04-12 DK DK07728049.3T patent/DK2032534T3/da active
- 2007-04-12 AT AT07728049T patent/ATE501121T1/de active
- 2007-04-12 DE DE602007013040T patent/DE602007013040D1/de active Active
- 2007-04-12 JP JP2009510383A patent/JP2009536962A/ja not_active Ceased
- 2007-04-12 ES ES07728049T patent/ES2362683T3/es active Active
- 2007-04-12 CN CN2007800172665A patent/CN101443312B/zh not_active Expired - Fee Related
- 2007-04-12 CA CA002651933A patent/CA2651933A1/en not_active Abandoned
- 2007-04-12 SI SI200730543T patent/SI2032534T1/sl unknown
- 2007-04-12 RS RS20110154A patent/RS51858B/sr unknown
-
2008
- 2008-12-04 NO NO20085052A patent/NO20085052L/no not_active Application Discontinuation
-
2011
- 2011-05-17 CY CY20111100477T patent/CY1111460T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY148406A (en) | 2013-04-30 |
| RS51858B (sr) | 2012-02-29 |
| DK2032534T3 (da) | 2011-04-26 |
| DE602007013040D1 (de) | 2011-04-21 |
| US20070265306A1 (en) | 2007-11-15 |
| BRPI0710856A2 (pt) | 2011-05-17 |
| HK1130053A1 (en) | 2009-12-18 |
| MX2008014439A (es) | 2009-01-21 |
| EP2032534A1 (de) | 2009-03-11 |
| SI2032534T1 (sl) | 2011-06-30 |
| HRP20110333T1 (hr) | 2011-06-30 |
| KR20090009971A (ko) | 2009-01-23 |
| NZ572714A (en) | 2010-08-27 |
| CN101443312B (zh) | 2011-07-06 |
| CN101443312A (zh) | 2009-05-27 |
| EP1854785A1 (de) | 2007-11-14 |
| EP2032534B1 (de) | 2011-03-09 |
| JP2009536962A (ja) | 2009-10-22 |
| NO20085052L (no) | 2008-12-04 |
| PL2032534T3 (pl) | 2011-08-31 |
| CY1111460T1 (el) | 2015-08-05 |
| ES2362683T3 (es) | 2011-07-11 |
| AU2007251663B2 (en) | 2012-04-05 |
| RU2412169C2 (ru) | 2011-02-20 |
| AU2007251663A1 (en) | 2007-11-22 |
| US20100004283A1 (en) | 2010-01-07 |
| WO2007131846A1 (en) | 2007-11-22 |
| RU2008148941A (ru) | 2010-06-20 |
| CA2651933A1 (en) | 2007-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602007013040D1 (de) | 4-Ä(3-FLUORPHENOXY)PHENYLMETHYLÜPIPERIDINMETHANiSULFONAT: VERWENDUNGEN, SYNTHESEVERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN | |
| NO20085068L (no) | Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
| CY1115058T1 (el) | Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης | |
| EA200900136A1 (ru) | Пирролопиримидины для фармацевтических композиций | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| EA201270505A1 (ru) | Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение | |
| ATE517882T1 (de) | Chinolinderivate | |
| EA201001585A1 (ru) | Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк) | |
| NO20073831L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer | |
| DK2150530T3 (da) | Substituerede sulfonamid-derivater | |
| NO20083514L (no) | Heterobicykliske sulfonamidderivater for behandling av diabetes | |
| UA102236C2 (uk) | Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| ATE442846T1 (de) | Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| NO20064078L (no) | Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter | |
| EA200970398A1 (ru) | Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр | |
| EA200901474A1 (ru) | Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе | |
| BRPI0411603A (pt) | 4-(aminometil)-piperidina benzamidas como antagonistas 5ht4 | |
| ATE495159T1 (de) | Diaminocyclohexan- und diaminocyclopentanderivate | |
| EA201171229A1 (ru) | Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях | |
| EA201070916A1 (ru) | Двойные фармакофоры - pde4-мускариновые антагонисты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2032534 Country of ref document: EP |